Literature DB >> 11033456

Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.

C András1, Z Csiki, I Gál, I Takács, L Antal, G Szegedi.   

Abstract

The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer. An average of 4.6 treatment cycles (3 12) was applied. Complete remission was not observed; partial remission was observed in 8 patients; in 13 patients no change occurred and progression was detected in 14 cases. Remission rate was 22.8%, mean response time was 5.2 (3 12) months, mean progress-free survival 5.6 (0 22) months. Mean survival from the start of treatment was 11.9 (1 42) months and from the establishment of the diagnosis 26.1 (3 60) months. Severe life-threatening side-effects did not occur; other side-effects such as fever, nausea, diarrhea, leucopenia, and anemia responded to drugs. Treatment by 5-FU and interferon, in accordance with other authors findings, improved survival and well-being of patients but no breakthrough has been achieved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033456     DOI: 10.1007/bf03032369

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  14 in total

Review 1.  Colorectal cancer--is there an alternative to 5-FU?

Authors:  H Bleiberg
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

2.  Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.

Authors:  Y Z Patt; A Hoque; R Lozano; R Pozdur; J Chase; H Carrasco; V Chuang; E S Delpassand; L Ellis; S Curley; M Roh; D V Jones
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

Authors:  N Kemeny; A Younes; K Seiter; D Kelsen; P Sammarco; L Adams; S Derby; P Murray; C Houston
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

4.  Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie.

Authors:  D Jaeck; P Bachellier; M Guiguet; K Boudjema; J C Vaillant; P Balladur; B Nordlinger
Journal:  Br J Surg       Date:  1997-07       Impact factor: 6.939

Review 5.  Current chemotherapeutic possibilities in the treatment of colorectal cancer.

Authors:  B van Triest; C J van Groeningen; H M Pinedo
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

Review 6.  Colorectal liver metastases.

Authors:  D Burke; T G Allen-Mersh
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

7.  Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.

Authors:  E C Gamelin; E M Danquechin-Dorval; Y F Dumesnil; P J Maillart; M J Goudier; P C Burtin; R G Delva; A H Lortholary; P H Gesta; F G Larra
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

8.  Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.

Authors:  P Ragnhammar; H Blomgren; D Edler; G Lundell; I Magnusson; T Sonnenfeld
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

9.  Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.

Authors:  J E Ferguson; P Hulse; P Lorigan; G Jayson; J H Scarffe
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.

Authors:  A Piga; S Cascinu; L Latini; M Marcellini; M Bavosi; L Acito; R Bascioni; L Giustini; G Francini; A Pancotti; G Rossi; M Del Papa; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.